Thomas Hospitals, Median age: 41.6 years Exclusion: Insertion: transorally (of prolonged monitoring) London, UK (range 17–75) Level: IV Not stated Placement: 6 cm proximal to the SCJ Indication: Duration: 96 hours Reflux symptoms and no Comparator: diagnosis of GORD on 24-, 48-, 72-hour Bravo pH monitoring catheter-based pH monitoring Ward et al. () Diagnostic yield 60 patients (58 patients Inclusion: Index test: Accuracy study had enough data to be Division of Not stated System: Bravo™ wireless capsule system Diagnostic yield included) Gastroenterology Exclusion: Insertion: transorally and Hepatology, 26 males, 34 females Level: IV Not stated Placement: 6 cm above the SCJ Mayo Clinic, Mean age 54 years Quality: Q2 Duration: 48 hours Jacksonville, (range 27–82) CX (no comparator) Florida, USA Indications: P2 Document GORD before surgery, possible GORD with negative PPI trial, evaluate response to PPI, possible GORD, chest pain, evaluate response to Stretta procedure, previous failed pH test Wenner, Johnsson Randomised 35 patients (31 patients Inclusion: Index test: Accuracy: et al. () crossover trial had enough data to be Patients referred for oesophageal pH System: Bravo™ wireless capsule system Concordance in acid Department of included) monitoring exposure time Insertion: transorally Surgery, Lund 15 males, 16 females Level: II Exclusion: Comparative diagnostic Placement: 6 cm above the SCJ University Hospital, Median age: 52 years yield Quality: 20/26 Patients with coagulopathy, severe Duration: 48 hours Lund, Sweden Median BMI: 27 (range oesophagitis/stricture, portal Comparator: 24–28) hypertension, a pacemaker, age <20 or System: Slimline (Medtronic) >70 years of age, previous Indications: Insertion: transnasally surgery, severe Typical reflux symptoms Placement: 5 cm above the upper border of cardiopulmonary disease, symptoms (55%) and atypical reflux
Thomas Hospitals, London, UK Level: IV Median age: 41.6 years (range 17–75) Indication: Reflux symptoms and no diagnosis of GORD on catheter-based pH monitoring Exclusion: Not stated Insertion: transorally Placement: 6 cm proximal to the SCJ Duration: 96 hours Comparator: 24-, 48-, 72-hour Bravo pH monitoring (of prolonged monitoring) Ward et al. () Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA Diagnostic yield study Level: IV Quality: Q2 CX (no comparator) P2 60 patients (58 patients had enough data to be included) 26 males, 34 females Mean age 54 years (range 27–82) Indications: Document GORD before surgery, possible GORD with negative PPI trial, evaluate response to PPI, possible GORD, chest pain, evaluate response to Stretta procedure, previous failed pH test Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm above the SCJ Duration: 48 hours Accuracy Diagnostic yield Wenner, Johnsson et al. () Department of Surgery, Lund University Hospital, Lund, Sweden Randomised crossover trial Level: II Quality: 20/26 35 patients (31 patients had enough data to be included) 15 males, 16 females Median age: 52 years Median BMI: 27 (range 24–28) Indications: Typical reflux symptoms (55%) and atypical reflux Inclusion: Patients referred for oesophageal pH monitoring Exclusion: Patients with coagulopathy, severe oesophagitis/stricture, portal hypertension, a pacemaker, age <20 or >70 years of age, previous surgery, severe cardiopulmonary disease, symptoms Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm above the SCJ Duration: 48 hours Comparator: System: Slimline (Medtronic) Insertion: transnasally Placement: 5 cm above the upper border of Accuracy: Concordance in acid exposure time Comparative diagnostic yield
1203-ContractedAssessmentReport-Catheter-free%20ambulatory%20pH%20test%20for%20GORD%20accessible.docx